| Título : |
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma |
| Tipo de documento : |
documento electrónico |
| Autores : |
Kenny Mauricio Gálvez Cárdenas, |
| Fecha de publicación : |
2021 |
| Títulos uniformes : |
Future Oncology
|
| Idioma : |
Inglés (eng) |
| Palabras clave : |
effectiveness ixazomib multiple myeloma proteasome inhibitor relapsed/refractory routine clinical practice |
| Resumen : |
Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. |
| Mención de responsabilidad : |
Roman Hájek, Jiri Minarík, Jan Straub, Ludek Pour, Alexandra Jungova, Jesus G Berdeja, Mario Boccadoro, Lucie Brozova, Andrew Spencer, Frits van Rhee, Jorge Vela-Ojeda, Michael A Thompson, Rafat Abonour, Ajai Chari, Gordon Cook, Caitlin L Costello, Faith E Davies, Vania TM Hungria, Hans C Lee, Xavier Leleu, Noemi Puig, Robert M Rifkin, Evangelos Terpos, Saad Z Usmani, Katja C Weisel, Jeffrey A Zonder, Magda Barinová, Matyáš Kuhn, Jirí Šilar, Lenka Cápková, Kenny Galvez, Jin Lu, Jennifer Elliott, Dawn Marie Stull, Kaili Ren & Vladimír Maisnar |
| Referencia : |
Future Oncol. 2021 Mar 26. |
| DOI (Digital Object Identifier) : |
10.2217/fon-2020-1225 |
| PMID : |
33769076 |
| Derechos de uso : |
CC BY-NC-ND |
| En línea : |
https://www.futuremedicine.com/doi/10.2217/fon-2020-1225 |
| Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis |
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, . - 2021. Obra : Future OncologyIdioma : Inglés ( eng)
| Palabras clave : |
effectiveness ixazomib multiple myeloma proteasome inhibitor relapsed/refractory routine clinical practice |
| Resumen : |
Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. |
| Mención de responsabilidad : |
Roman Hájek, Jiri Minarík, Jan Straub, Ludek Pour, Alexandra Jungova, Jesus G Berdeja, Mario Boccadoro, Lucie Brozova, Andrew Spencer, Frits van Rhee, Jorge Vela-Ojeda, Michael A Thompson, Rafat Abonour, Ajai Chari, Gordon Cook, Caitlin L Costello, Faith E Davies, Vania TM Hungria, Hans C Lee, Xavier Leleu, Noemi Puig, Robert M Rifkin, Evangelos Terpos, Saad Z Usmani, Katja C Weisel, Jeffrey A Zonder, Magda Barinová, Matyáš Kuhn, Jirí Šilar, Lenka Cápková, Kenny Galvez, Jin Lu, Jennifer Elliott, Dawn Marie Stull, Kaili Ren & Vladimír Maisnar |
| Referencia : |
Future Oncol. 2021 Mar 26. |
| DOI (Digital Object Identifier) : |
10.2217/fon-2020-1225 |
| PMID : |
33769076 |
| Derechos de uso : |
CC BY-NC-ND |
| En línea : |
https://www.futuremedicine.com/doi/10.2217/fon-2020-1225 |
| Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis |
|  |
Inicio
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma
